Retatrutide vs Tirzepatide: A Research-Use Comparison
A technical, laboratory-focused comparison of two incretin-system peptides frequently studied in metabolic research models. Strictly for in-vitro and non-human research use.
Mechanism of Action
Tirzepatide is a dual agonist that binds and activates both the GLP-1 receptor and the GIP receptor. In research models it is used to investigate combined incretin signaling on glucose homeostasis, insulin secretion, and body-composition markers.
Retatrutide is an investigational triple agonist targeting GLP-1, GIP, and the glucagon receptor. The added glucagon-receptor activity is studied for its effects on energy expenditure and hepatic lipid metabolism in research models, distinguishing it mechanistically from dual agonists.
Receptor Targets at a Glance
| Target | Tirzepatide | Retatrutide |
|---|---|---|
| GLP-1 receptor | Agonist | Agonist |
| GIP receptor | Agonist | Agonist |
| Glucagon receptor | — | Agonist |
| Classification | Dual agonist | Triple agonist |
Reference Research Vials
The specifications below reflect VAEL research-grade vials available for laboratory use. All material is supplied lyophilized for reconstitution per the researcher's protocol.
Choosing for a Research Protocol
Selection between a dual and triple agonist depends on the receptor pathways under investigation. Studies focused on combined incretin signaling typically reference tirzepatide; protocols extending into glucagon-receptor-mediated energy expenditure or hepatic lipid endpoints typically reference retatrutide. Both compounds are intended for controlled laboratory environments only.
For Research Use Only (RUO). Not for human or veterinary use, food, cosmetic, or therapeutic application. All products are sold to qualified researchers for laboratory study.